# Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

> **NCT05371197** · PHASE2 · UNKNOWN · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 26 (estimated)

## Conditions studied

- Colorectal Cancer
- Mismatch Repair-deficient (dMMR)
- Microsatellite Instability-high (MSI-H)
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Neoadjuvant therapy with PD-L1 inhibitor

## Key facts

- **NCT ID:** NCT05371197
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-05
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2022-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05371197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05371197, "Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05371197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*